• Kyodo

  • SHARE

Avigan, a candidate drug for treating COVID-19, has not shown apparent efficacy in treating the respiratory disease in clinical trials so far, raising doubts about its approval by the end of this month as sought by the government, sources familiar with the matter said Tuesday.

Interim results of clinical tests of Avigan on COVID-19 patients reported to the health ministry did not provide clear evidence of the drug’s effectiveness in limiting the progression of the disease, they said.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)